Factorial Partners LLC Has $193,000 Stock Position in Inogen, Inc. (NASDAQ:INGN)

Factorial Partners LLC lowered its position in Inogen, Inc. (NASDAQ:INGN) by 42.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,732 shares of the medical technology company’s stock after selling 17,500 shares during the quarter. Factorial Partners LLC owned approximately 0.10% of Inogen worth $193,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Monaco Asset Management SAM acquired a new position in shares of Inogen during the 2nd quarter worth $610,000. Panagora Asset Management Inc. acquired a new position in Inogen during the second quarter worth $256,000. Bank of New York Mellon Corp raised its holdings in Inogen by 8.1% during the second quarter. Bank of New York Mellon Corp now owns 97,132 shares of the medical technology company’s stock valued at $790,000 after buying an additional 7,240 shares in the last quarter. CWM LLC raised its holdings in Inogen by 2,185.9% during the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after buying an additional 6,339 shares in the last quarter. Finally, Stokes Family Office LLC lifted its position in shares of Inogen by 162.1% in the second quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company’s stock worth $927,000 after buying an additional 70,500 shares during the last quarter. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Trading Down 0.6 %

Shares of NASDAQ INGN opened at $11.26 on Wednesday. The firm has a market capitalization of $267.09 million, a price-to-earnings ratio of -2.71 and a beta of 1.05. Inogen, Inc. has a one year low of $4.13 and a one year high of $13.33. The business has a fifty day simple moving average of $10.51 and a 200 day simple moving average of $8.66.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.31. The firm had revenue of $88.77 million for the quarter, compared to analyst estimates of $82.50 million. Inogen had a negative net margin of 28.30% and a negative return on equity of 45.37%. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.42) EPS. On average, research analysts anticipate that Inogen, Inc. will post -1.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on INGN. StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.